Life Sciences

IBM and Pfizer to Accelerate Immuno-oncology Research with Watson for Drug Discovery

Share this post:

 

Watson Health and Pfizer Inc. today announced a collaboration that will utilize IBM Watson for Drug Discovery to help accelerate Pfizer’s research in immuno-oncology, an approach to cancer treatment that uses the body’s immune system to help fight cancer. Pfizer is one of the first organizations worldwide to deploy Watson for Drug Discovery, and the first to customize the cloud-based cognitive tool – tapping into Watson’s machine learning, natural language processing, and other cognitive reasoning technologies to support the identification of new drug targets, combination therapies for study, and patient selection strategies in immuno-oncology.

More Video Stories

Three Principles for Bringing Augmented Intelligence to Life Sciences

Written by Lauren O'Donnell | Blog Post, Life Sciences

In today’s healthcare system, we are not getting the value for the costs we are spending. It’s a complex issue with an equally complex set of potential solutions. But as the industry shifts to value-based care, we’ve reached a tipping point. ...read more